



October 2, 2014

Immune Design Added to Russell 2000(R) Index

SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today that the company was added to the Russell 2000[®] Index as part of Russell Investments' quarterly addition of select initial public offering (IPO) companies. Immune Design joined the index after the NASDAQ market closed on September 30, 2014. The stock also was added systematically to the appropriate Russell growth and value indexes.

The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe and is a subset of the Russell 3000[®] Index. Russell indexes are used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design's three on-going Immuno-oncology clinical programs are the product of its two synergistic discovery platforms: ZVex[™] and GLAAS[™]. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

CONTACT: Company Contact

Stephen R. Brady

Chief Business Officer

650-887-6717

Media Contact

Julie Rathbun

Rathbun Communications

julie@rathbuncomm.com

206-769-9219

Investor Contact

Robert H. Uhl

Westwicke Partners

robert.uhl@westwicke.com

858-356-5932